Back to Search
Start Over
OA07.06 Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)
- Source :
- Journal of Thoracic Oncology, Vol. 17, no.9, p. S22 (2022)
- Publication Year :
- 2022
-
Abstract
- INTRODUCTION : The combination of IO-CT has become the standard of care for patients with aNSCLC with a low or intermediate programmed death-ligand 1 (PD-L1) expression (<50%), and an option for patients with high PDL1 (≥50%) expression. There are no data available on the subsequent line (L2) outcomes after IO-CT. We aimed to assess the outcomes of various L2 treatments after IO-CT in aNSCLC. [...]
Details
- Database :
- OAIster
- Journal :
- Journal of Thoracic Oncology, Vol. 17, no.9, p. S22 (2022)
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1372936085
- Document Type :
- Electronic Resource